Xuanzhu Bio-B (02575) saw its shares surge more than 60% during the trading session. As of the time of writing, the stock was up 27.21%, trading at HK$54.6, with a turnover of HK$122 million.

Recently, Xuanzhu Bio announced that its self-developed Class 1 innovative drug, piroxiclib tablets, received approval from the National Medical Products Administration for a new indication. The drug can now be used in combination with aromatase inhibitors (AI) as initial endocrine therapy for patients with HR+/HER2- advanced breast cancer.

This marks the third approved indication for piroxiclib in China, following earlier approvals for use in combination with fulvestrant and as a monotherapy. With this approval, piroxiclib has become the first and only drug of its kind in China to cover the entire treatment course for HR+/HER2- advanced breast cancer, including first-line, second-line, and later-line therapies.

On March 9, Xuanzhu Bio-B was included in the Hong Kong Stock Connect list. The company's share price rose sharply by 8.30% on that day, with a turnover of HK$48.3875 million, significantly higher than the year-to-date average daily turnover of HK$22.44 million, representing an increase of approximately 116%. The following day, the daily turnover further climbed to HK$61.9559 million, indicating strong interest from Stock Connect investors in positioning themselves early.

The rapid rebound in trading activity and early investor positioning in Xuanzhu Bio's secondary market performance is largely attributed to market recognition of the company's clear "innovation-to-commercialization" investment thesis.